PURPOSE: To evaluate diagnostic and prognostic significance of plasma osteopontin (OPN) in patients with renal cell carcinoma (RCC). METHODS: The retrospective study included 80 patients with RCC (pN0M0, n = 32; pN1M0, n = 11; M1, and n = 37), and 52 healthy controls (27 females and 25 males). OPN, the bone marker bone-specific alkaline phosphatase (bALP) and carboxyterminal telopetide of type-I collagen (ICTP), and the enzymes alanine aminotransferase (ALAT), and gamma-glutamyltransferase (GGT) were evaluated together with Memorial Sloan-Kettering Cancer Center (MSKCC) laboratory parameters. Data were analyzed by receiver-operating characteristics (ROC), survival analysis, and Cox proportional hazards regression model. RESULTS: OPN and ICTP levels in RCC patients with distant metastases were significantly elevated (medians 115 and 4.7 microg/l, P < 0.001) compared to those without metastases (31.1 and 2.5 microg/l) and controls (28.9 and 2.1 microg/l) but did not differ between patients with bone or non-bone metastases. Both bALP and ALAT were not different between all study groups, while GGT was only increased in patients with non-bone metastases. In ROC analysis, OPN showed the best discrimination between patients with and without metastases (area under the curve: 0.888). High OPN values were associated with poor survival (Kaplan-Meier analysis, log-rank test, P = 0.002). Multivariate Cox regression with forward and backward stepwise elimination confirmed plasma OPN as independent predictive survival factor in RCC patients. CONCLUSIONS: Our results show that high plasma OPN levels are associated with distant metastases and poor survival in RCC patients. The use of OPN as potential marker to monitor new treatment strategies in patients with advanced RCC should be evaluated in prospective studies.
PURPOSE: To evaluate diagnostic and prognostic significance of plasma osteopontin (OPN) in patients with renal cell carcinoma (RCC). METHODS: The retrospective study included 80 patients with RCC (pN0M0, n = 32; pN1M0, n = 11; M1, and n = 37), and 52 healthy controls (27 females and 25 males). OPN, the bone marker bone-specific alkaline phosphatase (bALP) and carboxyterminal telopetide of type-I collagen (ICTP), and the enzymes alanine aminotransferase (ALAT), and gamma-glutamyltransferase (GGT) were evaluated together with Memorial Sloan-Kettering Cancer Center (MSKCC) laboratory parameters. Data were analyzed by receiver-operating characteristics (ROC), survival analysis, and Cox proportional hazards regression model. RESULTS:OPN and ICTP levels in RCCpatients with distant metastases were significantly elevated (medians 115 and 4.7 microg/l, P < 0.001) compared to those without metastases (31.1 and 2.5 microg/l) and controls (28.9 and 2.1 microg/l) but did not differ between patients with bone or non-bone metastases. Both bALP and ALAT were not different between all study groups, while GGT was only increased in patients with non-bone metastases. In ROC analysis, OPN showed the best discrimination between patients with and without metastases (area under the curve: 0.888). High OPN values were associated with poor survival (Kaplan-Meier analysis, log-rank test, P = 0.002). Multivariate Cox regression with forward and backward stepwise elimination confirmed plasma OPN as independent predictive survival factor in RCCpatients. CONCLUSIONS: Our results show that high plasma OPN levels are associated with distant metastases and poor survival in RCCpatients. The use of OPN as potential marker to monitor new treatment strategies in patients with advanced RCC should be evaluated in prospective studies.
Authors: M K Kashyap; A Kumar; N Emelianenko; A Kashyap; R Kaushik; R Huang; M Khullar; S K Sharma; S K Singh; A K Bhargave; S K Upadhyaya Journal: Biomarkers Date: 2005 Jul-Aug Impact factor: 2.658
Authors: Jae-Hoon Kim; Steven J Skates; Toshimitsu Uede; Kwong-kwok Wong; John O Schorge; Colleen M Feltmate; Ross S Berkowitz; Daniel W Cramer; Samuel C Mok Journal: JAMA Date: 2002-04-03 Impact factor: 56.272
Authors: Vivien H C Bramwell; Gordon S Doig; Alan B Tuck; Sylvia M Wilson; Katia S Tonkin; Anna Tomiak; Francisco Perera; Theodore A Vandenberg; Ann F Chambers Journal: Clin Cancer Res Date: 2006-06-01 Impact factor: 12.531
Authors: Akeila Bellahcène; Vincent Castronovo; Kalu U E Ogbureke; Larry W Fisher; Neal S Fedarko Journal: Nat Rev Cancer Date: 2008-03 Impact factor: 60.716
Authors: Saskia E Rademakers; Paul N Span; Johannes H A M Kaanders; Fred C G J Sweep; Albert J van der Kogel; Johan Bussink Journal: Mol Oncol Date: 2008-03-27 Impact factor: 6.603
Authors: Alka Jain; Dianalee A McKnight; Larry W Fisher; Elizabeth B Humphreys; Leslie A Mangold; Alan W Partin; Neal S Fedarko Journal: Clin Cancer Res Date: 2009-08-11 Impact factor: 12.531
Authors: Philip C Mack; Mary W Redman; Kari Chansky; Stephen K Williamson; Nichole C Farneth; Primo N Lara; Wilbur A Franklin; Quynh-Thu Le; John J Crowley; David R Gandara Journal: J Clin Oncol Date: 2008-09-08 Impact factor: 44.544
Authors: Sandra S McAllister; Ann M Gifford; Ashley L Greiner; Stephen P Kelleher; Matthew P Saelzler; Tan A Ince; Ferenc Reinhardt; Lyndsay N Harris; Bonnie L Hylander; Elizabeth A Repasky; Robert A Weinberg Journal: Cell Date: 2008-06-13 Impact factor: 41.582